drugset / Trial / NCT05273775

A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers

NCT05273775

Phase 1 Completed 22 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelBasic science

Summary

This is a drug-drug interaction study conducted in healthy volunteers to evaluate the effect of HRS5091 on CYP3A4, CYP2C9, CYP2C19, P-gp, BCRP and OATP1B1, using midazolam, s-warfarin, omeprazole, digoxin and rosuvastatin as probe drugs.

Timeline

Start
2022-04-29
Primary completion
2022-06-23
Completion
2022-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified
Subject HRS5091 Unknown
Subject Midazolam Small molecule
Subject Omeprazole Other / unclassified
Subject Rosuvastatin Small molecule
Subject Warfarin Small molecule
Background Vitamin K Unknown